No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. / Vilsbøll, Tina; Krarup, T; Madsbad, S; Holst, Jens Juul.

I: Diabetic Medicine, Bind 18, Nr. 2, 01.02.2001, s. 144-149.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Vilsbøll, T, Krarup, T, Madsbad, S & Holst, JJ 2001, 'No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose', Diabetic Medicine, bind 18, nr. 2, s. 144-149.

APA

Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2001). No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Medicine, 18(2), 144-149.

Vancouver

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Medicine. 2001 feb. 1;18(2):144-149.

Author

Vilsbøll, Tina ; Krarup, T ; Madsbad, S ; Holst, Jens Juul. / No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. I: Diabetic Medicine. 2001 ; Bind 18, Nr. 2. s. 144-149.

Bibtex

@article{867e9c4074c711dbbee902004c4f4f50,
title = "No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose",
abstract = "It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.",
author = "Tina Vilsb{\o}ll and T Krarup and S Madsbad and Holst, {Jens Juul}",
year = "2001",
month = feb,
day = "1",
language = "English",
volume = "18",
pages = "144--149",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

AU - Vilsbøll, Tina

AU - Krarup, T

AU - Madsbad, S

AU - Holst, Jens Juul

PY - 2001/2/1

Y1 - 2001/2/1

N2 - It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.

AB - It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.

M3 - Journal article

VL - 18

SP - 144

EP - 149

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 2

ER -

ID: 170290